Homozygous Arginine at Codon 72 of p53 Has No Prognostic Significance in Cervical Cancer

Ngan, Hextan Y.S.; Liu, Vincent Wing-Sun; Liu, Stephanie Si; Cheng, Danny; Ng, Tong-Yow; Wong, L. C.

doi:10.1159/000030119

Cited by 16 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no published studies on p53 polymorphism in Portuguese population, but the frequency of homozygous arginine p53 polymorphism has been reported as higher as 50% in many Caucasian groups ( 19,20, 58,59 ) in accordance with the high frequency detected in our samples. We found that p53 polymorphism has no value in predicting progression of CIN III which is in agreement with previous studies reporting that p53 polymorphism has no prognostic significance in cervical cancer ( 60,61 ) . In the present study, the p53 polymorphism was not related to HPV type, as reported by others ( 60–62 ) .…”

Section: Discussionsupporting

confidence: 90%

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Fonseca-Moutinho¹,

Cruz

Carvalho

et al. 2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

Abstract. Fonseca-Moutinho JA, Cruz E, Carvalho L, Prazeres HJM, de Lacerda MMP, da Silva DP, Mota F, de Oliveira CF. Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer 2004;14:911-920.There are no known biological markers or technologies to predict the natural history of an individual CIN III. The probability of progression is considered greater with the persistence of high-risk human papillomavirus (HPV) infection and age. p53 polymorphism has been associated with cervical carcinogenesis. Hormone-induced cervical cancer is mediated by estrogen receptor (ER) and progesterone receptor (PR). In cervical cancer, increased bcl-2 and Bax immunoreactivity is generally associated with a better prognosis. The purpose of this study was to evaluate the value of HPV 16 and HPV 18 typing and p53 codon polymorphism genotyping by polymerase chain reaction and ER, PR, bcl-2, and Bax expression by immunohistochemistry in predicting the CIN III clinical behavior of CIN III lesions. We studied the expression of these prognostic factors in the CIN III adjacent to squamous cell microinvasive carcinomas of the cervix (MIC) from 29 patients with FIGO stage IA1 cervical cancer and in 25 patients with CIN III and no documented focus of invasion. In the MIC group, only the CIN III was considered at least 2 mm away from the microinvasive complex. The ER, PR, bcl-2, and Bax immunoreactivity was scored as positive (>10% staining cells) and negative (<10% staining cells). No significant difference was observed between MIC and CIN III group concerning HPV infection and p53 polymorphism. The ER, PR, bcl-2, and Bax immunohistochemical expression was stronger and more frequent in the CIN III group. After multivariable analysis, coexpression of ER, PR, and bcl-2 was the only independent factor in defining low risk of progression for CIN III. Our study suggests that coexpression of ER, PR, and bcl-2 may be a useful tool in identifying the CIN III lesions with low risk of progression to cervical cancer.KEYWORDS: cervical microinvasive carcinoma, CIN III, immunohistochemistry, prognosis.Cervical cancer is one of the most frequent cancers in women, with an estimated worldwide incidence of about 371,000 new cases per year and an overall 5-year survival ranging from 44 to 66% for all clinical stages (1) .

show abstract

Section: Discussionsupporting

confidence: 90%

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Fonseca-Moutinho¹,

Cruz

Carvalho

et al. 2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…We found that p53 polymorphism has no value in predicting progression of CIN III which is in agreement with previous studies reporting that p53 polymorphism has no prognostic significance in cervical cancer (60,61) . In the present study, the p53 polymorphism was not related to HPV type, as reported by others (60)(61)(62) .…”

Section: Discussionsupporting

confidence: 92%

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Fonseca-Moutinho

Cruz

Carvalho

et al. 2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

There are no known biological markers or technologies to predict the natural history of an individual CIN III. The probability of progression is considered greater with the persistence of high-risk human papillomavirus (HPV) infection and age. p53 polymorphism has been associated with cervical carcinogenesis. Hormone-induced cervical cancer is mediated by estrogen receptor (ER) and progesterone receptor (PR). In cervical cancer, increased bcl-2 and Bax immunoreactivity is generally associated with a better prognosis. The purpose of this study was to evaluate the value of HPV 16 and HPV 18 typing and p53 codon polymorphism genotyping by polymerase chain reaction and ER, PR, bcl-2, and Bax expression by immunohistochemistry in predicting the CIN III clinical behavior of CIN III lesions. We studied the expression of these prognostic factors in the CIN III adjacent to squamous cell microinvasive carcinomas of the cervix (MIC) from 29 patients with FIGO stage IA1 cervical cancer and in 25 patients with CIN III and no documented focus of invasion. In the MIC group, only the CIN III was considered at least 2 mm away from the microinvasive complex. The ER, PR, bcl-2, and Bax immunoreactivity was scored as positive (>10% staining cells) and negative (<10% staining cells). No significant difference was observed between MIC and CIN III group concerning HPV infection and p53 polymorphism. The ER, PR, bcl-2, and Bax immunohistochemical expression was stronger and more frequent in the CIN III group. After multivariable analysis, coexpression of ER, PR, and bcl-2 was the only independent factor in defining low risk of progression for CIN III. Our study suggests that coexpression of ER, PR, and bcl-2 may be a useful tool in identifying the CIN III lesions with low risk of progression to cervical cancer.

show abstract

“…In nasopharyngeal carcinoma, the Pro/Pro genotype was reported to be associated with a poor prognosis [20]. However, some studies demonstrated a poor association of p53 codon 72 polymorphism with prognosis [13,14]. In the present study, the presence of the Pro allele was associated with localized/low-grade prostate cancer, although the sample number was small.…”

Section: Discussioncontrasting

confidence: 52%

A p53 Codon 72 Polymorphism Associated with Prostate Cancer Development and Progression in Japanese

et al. 2003

View full text Add to dashboard Cite

An association between the Pro/Pro genotype of p53 codon 72 and a lower risk of prostate cancer in Caucasians was recently reported. However, the association of this polymorphism with prostate cancer risk in a Japanese population has not been clarified. We performed a case-control study consisting of 114 prostate cancer patients and 105 noncancer controls. Sixty-nine percent (79 of 114) of the patients had a positive family history. The genotypic frequencies in the controls were 39.0% for Arg/Arg, 54.3% for Arg/Pro and 6.7% for Pro/Pro; they were in Hardy-Weinberg equilibrium. When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53–1.88] and 2.80 (95% CI 1.04–7.53), respectively. When stratification of cases was performed based on clinical stage (localized or metastatic cancer) and pathological grade (a Gleason score of <7 or ≧7), there tended to be a greater number of patients with localized cancers among those patients with the Arg/Pro genotype than among those with the Arg/Arg genotype (overall cases: age-adjusted OR 0.36, 95% CI 0.13–1.00, p = 0.049; positive family history cases: age-adjusted OR 0.25, 95% CI 0.075–0.84, p = 0.025). In addition, there tended to be a greater number of patients with low-grade cancers among those with the Pro/Pro genotype than among those with other genotypes (overall cases: age-adjusted OR 0.41, 95% CI 0.13–1.30, p = 0.13; positive family history cases: age-adjusted OR 0.20, 95% CI 0.004–0.89, p = 0.035). The present findings suggest that the Pro/Pro genotype of p53 codon 72 played a role in prostate cancer susceptibility in a Japanese population. However, the Pro allele did not appear to worsen such clinical parameters as clinical stage or pathological grade.

show abstract

Homozygous Arginine at Codon 72 of p53 Has No Prognostic Significance in Cervical Cancer

Cited by 16 publications

References 18 publications

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

A p53 Codon 72 Polymorphism Associated with Prostate Cancer Development and Progression in Japanese

Contact Info

Product

Resources

About